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Dr Brian Godman and Professor Mohamed Azmi Hassali review Rida et al regarding pricing strategies 
for pharmaceuticals in developing countries. 
 
Rida and Ibrahim are to be congratulated on their extensive review of ongoing pricing strategies in 
developing countries (1), also referred to as lower and middle income countries (LMICs). These 
include advocating policies regarding mark-ups for pharmaceuticals, pricing formulae for medicines, 
external reference pricing, as well as encouraging greater use of generics (2-4).  However, there are 
concerns over external reference pricing (ERP), especially for new medicines where pharmaceutical 
companies are potentially delaying launch or not launching in some countries to maintain high prices 
(5). There are also concerns over the ability to rapidly obtain low prices for generics if prices under 
ERP systems are only reviewed annually or biannually. Aggressive pricing policies in the Netherlands, 
including 3-monthly tendering, led to prices of generic omeprazole and simvastatin dropping to just 
2% of the originator price in a short time period (6). In Sweden, compulsory generic substitution with 
the lowest priced generic also led to rapid price erosion following generic availability. Prices fell further 
following the instigation of monthly auctions where the cheapest generic was guaranteed a substantial 
proportion of the market the following month (7, 8). 
 
The prices of pharmaceuticals are a particular issue in LMICs, where medicines can account for up to 
60% of total healthcare expenditures, and where up to 90% of the population purchase medicines 
through co-payments (9, 10). High co-payments impact on adherence of non-communicable diseases 
(NCDs) as well as on access to biologicals to treat immunological diseases (11-13). This is a concern 
with NCDs as for example, currently 3 out of 4 patients with hypertension live in LMICs (14).  As 
mentioned by Rida and Ibrahim, promoting generics is a major way to reduce prices and enhance 
access to appropriate medicines (1, 10, 15, 16). Although things are changing (10, 16), to date there 
have only been a limited number There are also a comparative lack of strategies in place to combat 
the activities of pharmaceutical companies who are promoting their branded medicines and negatively 
impacting on the use of generics (17). The lack of promotion of generics can often be coupled with a 
lack of formal pricing strategies for generics (8). This can be a major concern for countries and 
patients treating NCDs as generics for NCDs can be manufactured and distributed for as little as 
US$1/ patient/ month (18, 19).  
 
The lack of formal pricing strategies in place for generics in LMICs contrasts sharply with European 
countries where there are multiple formal pricing policies. These can be collated under three main 
themes (10, 20, 21) and include (8): regulated systems (prescriptive pricing) where there are 
established rules for the pricing of generics, as seen in Belgium, Croatia, France, Hungary, Norway 
and Poland; free pricing - where manufacturers are (relatively) free to set prices of generics, as seen 
in Germany, Netherlands, Sweden and the UK; however, typically there are programmes in place to 
obtain low prices; or a mixed approach ± which is a combination of the two different approaches, as 
currently seen in Austria (10, 22-25). 
 
As a result of the different pricing policies, there can be substantial price differences for generics (8, 
21, 26). Overall, generic prices can vary by up to 36 fold across countries depending on the pricing 
policies (27), with prices generally lower in countries with higher consumption of generics (28). This is 
independent of the size of the country (29, 30). Different countries across Europe and other parts of 
the world have also used a variety of other approaches to promote the use of generics. These include 
educational approaches, financial incentives and laws. Laws include compulsory generic substitution, 
as seen in Sweden, or compulsory INN prescribing, as seen in Lithuania (7, 29).  
 
Despite the efforts being made, there are still a number of barriers that need to be addressed to 
enhance the prescribing and dispensing of generics, especially in LMICs (10, 31, 32). These include 
addressing fears associated with generic substitution that are enhanced by concerns over the efficacy 
and safety of generics (33, 34). Such fears resulted in Hassali et al. developing a list of requirements 
that should be met to enhance successful substitution (35). Education needs include encouraging 
high international nonproprietary name (INN) prescribing which is advocated by the WHO for non-
controversial products, as seen in Scotland where rates are close to the 100% (8, 36). Financial 
incentives include greater patient co-payments for branded products of the same molecule, which is 
typically practiced across Europe (21). Potential initiatives can also include reducing financial 
disincentives to the prescribing of generics, as currently seen in China. Here, both hospitals and 
physicians need to prescribe branded products with associated procured discounts to enhance their 
incomes (37). This is in addition to the measures mentioned by Rida and Ibrahim in their Table (Table 
1) (1). 
 
It is important that appropriate care is taken when introducing pricing policies for generics. In 2012, 
the South Korean government set the same maximum reimbursement price for originators and 
generics in an attempt to make the market more competitive, building on earlier reforms mentioned by 
Rida and Ibrahim (Table 1) (38). However, given the concerns that still exist among physicians in 
Korea regarding generics, the opposite was achieved. The price dispersion between different 
generics significantly decreased and originator utilization significantly increased (38). A similar 
situation was seen when compulsory INN prescribing was introduced. Implementation of this policy in 
Abu Dhabi, UAE, did not achieve the desired results as physicians were not incentivised to 
preferentially prescribe the generic medicines and pharmacists¶ remuneration was not altered to 
preferentially dispense the cheapest INN product (39). 
 
Many countries have also implemented a variety of approaches to the pricing and reimbursement of 
new medicines. Whilst all countries use critical appraisal techniques to assess the level of health gain 
with new medicines as part of pricing negotiations, some countries use this as a basis for pricing 
negotiations, e.g. Austria, France and Germany. Othersuse this information to develop economic 
parameters, such as the extent of an increase in quality adjusted life years with the new medicine with 
or without a budget impact analysis (QALYs) (40-42). One concern is that most countries that utilise 
QALYs do not set thresholds, which can be exploited by pharmaceutical companies, especially in 
emotive disease areas such as cancer and orphan diseases (40, 43, 44).  
 
There is also growing use of risk sharing arrangements brought about by the ever increasing prices of 
new medicines and issues of affordability in European countries (41, 45, 46). This contrasts sharply 
with LMIC countries where currently there are few formal pricing approaches for new medicines, as 
discussed by Rida and Ibrahim (1). Examples of pricing strategies that could be considered by LMICs 
when funding new medicines include those currently instigated in Austria (41, 47). This is in addition 
to ERP as advocated by the WHO (4). In Austria, new medicines that are similar to existing standards 
are expected to be priced lower than the current standard prices for reimbursement (48). New 
medicines that have added benefit can potentially command up to 10% more than the current 
standard prices, with prices for new medicines that are deemed to have substantially more added 
value, being allowed to have prices similar to comparable European countries  endorsed by health 
economic evaluations (48). In the case of LMICs, this would mean prices similar to other LMICs with 
similar economic situations, as seen in Europe (3). With only a few new medicines typically seen as 
innovative, this means that most new medicines will be priced below or just above current standards 
(41, 47), greatly increasing affordability and access. 
 
In conclusion, Rida and Ibrahim¶VUHVHDUFKKDVEHHQextensive. They have highlighted the need for 
LMICs to develop suitable pricing strategies for medicines to enhance access to affordable medicines. 
This is essential, given rising rates of NCDs and other diseases. There is an opportunity for LMICs to 
learn from other countries, such as those in Europe who are developing strategies to cope with 
growing resource pressures on healthcare systems and the need to  maintain equitable and 
comprehensive healthcare for all (8, 41). 
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